MX2015001348A - Cocleatos hechos con fosfatidilserina de soja. - Google Patents

Cocleatos hechos con fosfatidilserina de soja.

Info

Publication number
MX2015001348A
MX2015001348A MX2015001348A MX2015001348A MX2015001348A MX 2015001348 A MX2015001348 A MX 2015001348A MX 2015001348 A MX2015001348 A MX 2015001348A MX 2015001348 A MX2015001348 A MX 2015001348A MX 2015001348 A MX2015001348 A MX 2015001348A
Authority
MX
Mexico
Prior art keywords
soy phosphatidylserine
cochleates
cochleates made
phosphatidylserine
soy
Prior art date
Application number
MX2015001348A
Other languages
English (en)
Other versions
MX361155B (es
Inventor
Raphael Mannino
Ruying Lu
Original Assignee
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers filed Critical Univ Rutgers
Publication of MX2015001348A publication Critical patent/MX2015001348A/es
Publication of MX361155B publication Critical patent/MX361155B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se utiliza fosfatidilserina de soja de baja pureza o no purificada, para preparar cocleatos. Los cocleatos contienen aproximadamente 40-74% de fosfatidilserina de soja, un catión multivalente y un activo biológico. Un cocleato preferido contiene el agente anti-fúngico anfotericina B.
MX2015001348A 2012-07-30 2013-07-30 Cocleatos hechos con fosfatidilserina de soja. MX361155B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261677414P 2012-07-30 2012-07-30
US201361835825P 2013-06-17 2013-06-17
PCT/US2013/052756 WO2014022414A1 (en) 2012-07-30 2013-07-30 Cochleates made with soy phosphatidylserine

Publications (2)

Publication Number Publication Date
MX2015001348A true MX2015001348A (es) 2016-03-04
MX361155B MX361155B (es) 2018-11-28

Family

ID=50028476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001348A MX361155B (es) 2012-07-30 2013-07-30 Cocleatos hechos con fosfatidilserina de soja.

Country Status (14)

Country Link
US (5) US20150297725A1 (es)
EP (2) EP2879502B1 (es)
JP (2) JP6444865B2 (es)
KR (1) KR102115718B1 (es)
CN (1) CN105050409B (es)
AU (1) AU2013296651B2 (es)
BR (1) BR112015001892B1 (es)
CA (1) CA2879931C (es)
DK (1) DK2879502T3 (es)
ES (1) ES2688397T3 (es)
HK (1) HK1211181A1 (es)
MX (1) MX361155B (es)
RU (1) RU2659729C2 (es)
WO (1) WO2014022414A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2688397T3 (es) * 2012-07-30 2018-11-02 Matinas Biopharma Nanotechnologies, Inc. Cocleatos hechos con fosfatidilserina de soja
WO2016141203A1 (en) 2015-03-03 2016-09-09 Aquarius Biotechnologies, Inc. Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent
CN108136212A (zh) * 2015-04-22 2018-06-08 马丁尼斯生物制药纳米技术公司 用于治疗分枝杆菌感染和肺病的组合物和方法
KR20180014790A (ko) * 2015-06-18 2018-02-09 마티나스 바이오파마 나노테크놀로지스, 인코포레이티드 염증성 질환 또는 병태를 치료하기 위한 조성물 및 방법
CN108366974A (zh) * 2015-12-16 2018-08-03 维韦克·阿南德·帕拉库尔 天然化合物的三分子复合物
US11123295B2 (en) 2016-07-12 2021-09-21 Matinas Biopharma Nanotechnologies, Inc. Encholeated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections
CA3076336A1 (en) * 2017-09-20 2019-03-28 Atopic Medical, LLC Compositions and methods for treating and ameliorating respiratory conditions and inflammation of mucosa
KR101989789B1 (ko) 2017-11-30 2019-06-18 (주) 에이치엔에이파마켐 포스파티딜세린/음이온계면활성제/염화칼슘을 이용한 코킬레이트
ES1245259Y (es) 2019-05-10 2020-08-24 Bionova Slu Emulsiones de los cannabinoides del aceite de cáñamo
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
WO2023183297A1 (en) * 2022-03-21 2023-09-28 The Board Of Trustees Of The University Of Illinois Ion channel prosthetic compositions comprising lipid-coated crystals of amphotericin b
WO2024039729A1 (en) 2022-08-16 2024-02-22 Matinas Biopharma Nanotechnologies, Inc. Antifungal agent encapsulated in a lipid nanocrystal for treating mucormycosis
WO2024039733A1 (en) 2022-08-16 2024-02-22 Matinas Biopharma Nanotechnologies, Inc. Methods of controlling lipid nanocrystal particle size and lipid nanocrystals produced by such methods

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
GB8919172D0 (en) * 1989-08-23 1989-10-04 Univ Nottingham Useful composition
JPH0550062A (ja) 1991-05-29 1993-03-02 Toray Ind Inc 水溶液の浄化法
CA2123780A1 (en) * 1991-12-11 1993-06-24 Ronald A. Pieringer Amphotericin b composition with enhanced antifungal activity
WO1994012155A1 (en) * 1992-12-02 1994-06-09 Vestar, Inc. Antibiotic formulation and process
US6663885B1 (en) * 1993-03-15 2003-12-16 A. Natterman & Cie Gmbh Aqueous liposome system and a method for the preparation of such a liposome system
US5554382A (en) * 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
AU4981896A (en) * 1995-02-14 1996-09-04 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering liposome-loadable drugs
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
JP3697189B2 (ja) * 2001-01-11 2005-09-21 日清オイリオグループ株式会社 リン脂質の塩基交換方法
DE10109898A1 (de) * 2001-02-21 2002-09-05 Novosom Gmbh Lipide mit veränderlicher Ladung
CA2444529C (en) * 2001-04-20 2010-11-23 The University Of British Columbia Micellar drug delivery systems for hydrophobic drugs
US20030219473A1 (en) * 2002-03-26 2003-11-27 Leila Zarif Cochleates made with purified soy phosphatidylserine
DE10228680A1 (de) * 2002-06-27 2004-01-22 Holden Development Limited, Tortola Grundlage für transdermale Formulierungen (PTF)
AU2003254598A1 (en) 2002-08-06 2004-02-23 Tuo Jin Cochleates without metal cations as the bridging agents
WO2004037271A1 (en) * 2002-10-25 2004-05-06 Vasogen Ireland Limited Cyclooxygenase regulation with ps liposomes
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
AU2003296923B2 (en) * 2002-11-01 2010-03-04 Biodelivery Sciences International, Inc. Geodate delivery vehicles
WO2004064805A1 (en) * 2003-01-15 2004-08-05 Biodelivery Sciences International, Inc. Cochleate preparations of fragile nutrients
EP1631669A2 (en) * 2003-04-09 2006-03-08 Biodelivery Sciences International, Inc. Cochleate compositions directed against expression of proteins
EP1624858B1 (en) * 2003-04-09 2018-06-06 Rutgers, the State University of New Jersey Novel encochleation methods
JP4891522B2 (ja) * 2003-10-03 2012-03-07 株式会社ファンケル 血清ｇｏｔ、ｇｐｔ改善剤
CU20080215A7 (es) 2008-11-19 2012-06-21 Inst Finlay Vacunas unitemporales
WO2010091090A1 (en) * 2009-02-03 2010-08-12 Biodelivery Sciences International, Inc. Cochleate compositions and methods of use
JP5621204B2 (ja) * 2009-03-31 2014-11-12 日油株式会社 血管老化予防剤
US20100239521A1 (en) * 2010-06-01 2010-09-23 Mohammad Reza Mozafari Method for the preparation of micro- and nano-sized carrier systems for the encapsulation of bioactive substances
EP2689775A1 (en) * 2012-07-25 2014-01-29 Instituto Finlay, Centro de Investigacion-Produccion de vacunas y sueros Cochleate with only one mamp
ES2688397T3 (es) 2012-07-30 2018-11-02 Matinas Biopharma Nanotechnologies, Inc. Cocleatos hechos con fosfatidilserina de soja

Also Published As

Publication number Publication date
JP6751424B2 (ja) 2020-09-02
US20210038722A1 (en) 2021-02-11
EP2879502A1 (en) 2015-06-10
CN105050409B (zh) 2018-05-25
BR112015001892A2 (pt) 2017-07-04
US9370572B2 (en) 2016-06-21
HK1211181A1 (en) 2016-05-20
KR102115718B1 (ko) 2020-05-28
ES2688397T3 (es) 2018-11-02
US11964019B2 (en) 2024-04-23
CA2879931A1 (en) 2014-02-06
US20150297725A1 (en) 2015-10-22
CA2879931C (en) 2020-12-15
DK2879502T3 (en) 2018-10-15
AU2013296651B2 (en) 2017-03-02
AU2013296651A1 (en) 2015-03-19
MX361155B (es) 2018-11-28
JP6444865B2 (ja) 2018-12-26
US10716860B2 (en) 2020-07-21
BR112015001892A8 (pt) 2017-10-10
US9775907B2 (en) 2017-10-03
RU2015105881A (ru) 2016-09-20
EP2879502A4 (en) 2016-03-09
KR20150107707A (ko) 2015-09-23
EP2879502B1 (en) 2018-09-05
JP2015528021A (ja) 2015-09-24
CN105050409A (zh) 2015-11-11
EP3461338A1 (en) 2019-04-03
US20150140074A1 (en) 2015-05-21
US20180185491A1 (en) 2018-07-05
RU2659729C2 (ru) 2018-07-03
BR112015001892B1 (pt) 2021-02-02
US20150147380A1 (en) 2015-05-28
JP2018203750A (ja) 2018-12-27
WO2014022414A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
MX361155B (es) Cocleatos hechos con fosfatidilserina de soja.
CL2013000238A1 (es) Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos.
EP3045485A4 (en) Polyisocyanate modified with sulphamic acid, preparation method therefor and use thereof
MX370903B (es) Composiciones de ácido percarboxílico estables y sus usos.
WO2012100224A3 (en) Preparation of metal-triazolate frameworks
ECSP11010905A (es) Uso de ditiina-tetracarboximidas para combatir hongos fitopatógenos
IN2015DN03763A (es)
MX2015013727A (es) Composicion para preparacion de uso externo con permeabilidad transdermica mejorada.
MX352985B (es) Formulaciones desinfectantes topicas y uso de las mismas.
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
MY170302A (en) Process for the preparation of an aqueous solution comprising at least one earth alkali hydrogen carbonate and its use
CA2798214C (en) Vaccine against beta-herpesvirus infection and use thereof
TWD168530S (zh) 容器
MY161601A (en) Films and compositions comprising the same
WO2012135432A3 (en) Dyes for membranes and biological structures
WO2013123046A3 (en) Cathode buffer materials and related devices and methods
MX2015017638A (es) Polioles que contienen tanino, su producción y su uso.
CL2015001681A1 (es) Unidad solida con alto contenido en fexofenadina; procedimiento de preparacion; y uso de la misma como antihistaminico, broncodilatador y/o para el tratamiento de alergias y/o urticarias.
NZ709925A (en) Temperature stable cloquintocet-mexyl aqueous compositions
WO2014140911A3 (en) Diagnostic and therapeutic methods relating to microrna-144
WO2015001524A3 (en) Stabilization of rose dedifferentiated cells
WO2014198913A3 (en) Novel piscirickettsia salmonis isolate
BR112015023730A2 (pt) uso de sedoeptulose como suplemento nutricional
WO2013095994A3 (en) Transparent aqueous fragrance microemulsions
BG111577A (bg) Пропусклив устойчив бетон

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: CELLDEX THERAPEUTICS, INC.

FG Grant or registration